Leveraging Novel Vaccine Design Strategies for Effective HIV Vaccines
RNA Salon Kenya and KEMRI CVR hosted a virtual seminar exploring how rational vaccine design, mRNA platforms, and broadly neutralizing antibodies are shaping the future of HIV vaccine development.
7/1/20263 min read
RNA Salon Kenya, in collaboration with KEMRI CVR, hosted an insightful virtual seminar on “Leveraging novel vaccine design strategies and delivery platforms to develop effective HIV vaccines.” The session was led by Dr. Michelle Muthui, a Post-Doctoral Researcher at KEMRI-Wellcome Trust, and moderated by Dr. Doreen Lugano, also from KEMRI-Wellcome Trust.
The discussion began by highlighting why developing an effective HIV vaccine remains one of the most difficult challenges in modern immunology. HIV is highly diverse, meaning the virus varies greatly between individuals and across global populations. This makes it difficult to design a single vaccine that can protect against many circulating strains. The virus also integrates into the host genome early during infection, allowing it to hide from immune clearance. In addition, HIV’s envelope protein is heavily coated with host-derived glycans, which can shield important immune target sites from antibody recognition.
A major focus of the session was the role of broadly neutralizing antibodies, commonly known as bnAbs. These are special antibodies capable of neutralizing many different HIV strains by targeting conserved sites of vulnerability on the HIV envelope spike protein. Unlike ordinary antibodies that may only recognize a narrow range of viral variants, bnAbs offer a promising route toward broad protection. However, inducing these antibodies through vaccination is not straightforward because many bnAbs have unusual features that are not naturally favored by the immune system.
Dr. Muthui explained that earlier HIV vaccine trials have provided important lessons, even though most have not achieved strong or lasting protection. Trials such as RV144 showed modest and transient protection, while others, including HVTN 702 and AMP studies, helped researchers better understand the immune responses needed for protection. These studies have shifted the field from an older empirical approach, where many vaccine candidates were tested to see what worked, toward a more rational design approach. In rational vaccine design, scientists first identify the immune response needed for protection, then design vaccines that can guide the immune system toward producing that response.
One promising strategy discussed was germline targeting, which aims to activate rare naïve B cells that have the potential to mature into bnAb-producing cells. This approach uses specially designed immunogens to begin the immune training process, followed by booster vaccines that guide antibody maturation step by step. The eOD-GT8 60mer immunogen was presented as an example of this strategy, designed to prime VRC01-class antibody responses that target the CD4 binding site on HIV.
The session also highlighted findings from the IAVI G003 Phase 1 trial, conducted among healthy HIV-uninfected adults in Rwanda and South Africa. The trial evaluated the safety and immunogenicity of eOD-GT8 60mer delivered as an mRNA vaccine. Encouragingly, the vaccine was generally well tolerated, with no serious adverse events reported among the 18 participants. The main safety observation was mild to moderate transient reactogenicity, while two participants experienced delayed itching that resolved.
Importantly, immune analyses showed that the mRNA-delivered eOD-GT8 60mer was immunogenic in African trial participants. It elicited antibodies against the CD4 binding site and generated antigen- and epitope-specific IgG memory B cells. Notably, VRC01-class responses were observed in 17 out of 18 participants, suggesting that this vaccine platform can successfully prime the type of immune responses needed for future bnAb development.
A key takeaway was that population genetics may influence vaccine responses. The frequency of certain naïve B cell precursors and IGHV1-2 genetic variants can vary between populations, potentially affecting how individuals respond to germline-targeting vaccines. This reinforces the importance of conducting HIV vaccine research in African populations, where the burden of HIV remains high and where vaccine performance must be directly evaluated.
Overall, the seminar emphasized that while HIV vaccine development remains complex, the field is moving into a more precise and promising era. By combining rational immunogen design, mRNA delivery platforms, germline targeting, and population-specific clinical studies, researchers are getting closer to strategies that may one day generate broad and durable protection against HIV.
